We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BZU:MILBuzzi Spa Analysis

Data as of 2026-03-12 - not real-time

€43.36

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Buzzi S.p.A. trades at roughly €43, well below its DCF‑derived fair value of €68, implying a material upside potential. The stock’s low trailing PE around 9x earnings and a modest price‑to‑book near 1.2× suggest it is currently undervalued relative to peers. Strong cash generation (operating cash flow > €0.9 bn) and a generous dividend yield of ~1.6% with a low payout ratio underscore the sustainability of its income stream.
Technically, the price sits beneath the 20‑, 50‑ and 200‑day moving averages and the MACD histogram remains negative, signaling bearish momentum, while the RSI hovering below 40 points to a mild oversold condition that could spark a short‑term bounce toward the nearby support at €41.7. High 30‑day volatility (~42%) and a notable max drawdown of 25% highlight price swings, but the low beta and increasing volume mitigate broader market risk. The company’s diversified footprint across Europe, the U.S., and emerging markets cushions geographic exposure, though its debt‑to‑equity ratio above 9 raises leverage concerns. Overall, the blend of attractive valuation, solid fundamentals, and a supportive dividend makes Buzzi a compelling candidate for investors with a medium‑ to long‑term horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below key moving averages
  • Bearish MACD histogram
  • RSI indicating oversold conditions near support

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap to DCF fair value
  • Strong cash flow and low payout ratio supporting dividend
  • Steady revenue growth and solid ROE

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified geographic exposure reducing concentration risk
  • Undervalued metrics combined with sustainable dividend
  • Resilient operating margins despite cyclical sector dynamics

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin20.30%
P/E Ratio9.4
ROE14.44%
ROA6.89%
Debt/Equity9.10
P/B Ratio1.2
Op. Cash Flow€943.7M
Free Cash Flow€641.1M

Technical Analysis

TrendNeutral
RSI35.1
Support€41.70
Resistance€51.45
MA 20€46.90
MA 50€48.98
MA 200€48.07
MACDBearish
VolumeIncreasing
Fear & Greed Index78.16

Valuation

Fair Value€68.72
Target Price€54.73
Upside/Downside26.21%
GradeUndervalued
TypeBlend
Dividend Yield1.59%

Risk Assessment

Beta0.55
Volatility41.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.